Asia Pacific is expected to lead
the market promoting the utilization of immunoassays with the rise in
infectious diseases
Regional segmentation of the Immunoassay
Instruments Market by Coherent Market Insights comprises North America,
Europe, Asia-Pacific, Latin America and Middle East and Africa. North America
is expected to dominate the global market owing to the rising demand for
technologically advanced clinical diagnostic analyzers capable to perform
multiple immunoassays simultaneously. According to the article published in
Genetic Engineering and Biotechnology News (GEN), the market for infectious
disease testing in the U.S. is expected to grow from U.S. $168 billion in 2015
to U.S. $209 billion in 2020 owing to the upsurge of infectious diseases.
Additionally, the rising grants from the government and the private healthcare
agencies, contributing towards the development of technology and
commercialization of immunoassay analyzers, thereby raising the market in North
America. The immunoassay instruments market is expected to boost in Asia
Pacific owing to the rising research activities in microbiology sector,
increasing the prevalence of infectious and chronic diseases like cholera,
tuberculosis, typhoid, autoimmune diseases and rising government healthcare
grants. For instance, China directed immunoassay market at an estimated U.S.
$626 million in 2013 and is estimated to reach U.S. $1309 million by 2018.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/942
Immunoassay Instruments are
bioanalytical devices used to perform automated biochemical tests for the
detection of various substances or specific proteins in the samples. The
immunoassay instruments, also known as analyzers are used in hospitals and
clinical laboratories to detect the concentration and presence of analytes in
the blood, plasma and urine samples. The immunoassay tests rely on the ability
of antibody binding to a specific structure of molecule present in the
analytes. The concentration of proteins is measured using the specific
antigen-antibody binding properties. The quantification and identification of
proteins in the analyte sample is done by using the antibody as a reagent. The
advantages of using immunoassay instruments are the minimal human resistance,
simultaneous screening of multiple samples. The high sensitivity, reliability,
and applicability to a range of compounds, distinctive selective and detection
abilities at extremely low concentrations of nanogram to pictogram make
immunoassays a powerful tool.
A wide variety to address health
problems drives the immunoassay instruments market
According to the Disease
Prevention and Health Promotion estimates in 2017, the immunoassay techniques
have prevented up to 14 million lives with early diagnosis, reducing the
healthcare costs by $9.9 billion. The adoption of automated techniques to test
various substances including antibiotic, anticonvulsant or cardiac glycoside
drug concentration determination, cancer markers, endocrine hormone testing
drives the market. Rising prevalence of infectious diseases with early
diagnosis, prevention, and treatment is the main factor boosting the demand for
compact consumable products and instruments in the healthcare sector. The
launch of various FDA approved innovative products is expected to fuel the
commercialization of immunoassay instruments significantly in the forecast
period. For instance, the launch of fluorescence scanning portable instrument
ichroma II and enzyme-linked immunosorbant assay (ELISA) test cartridge by
iStat cardiac Troponin I.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/immunoassay-instruments-market-942
Improved workflow owing to ease
and comprehensive technology are the prominent factors estimated to boost the
automated immunoassay instrument market
The launch of automated
chemiluminescence immunoassay instrument by Abbott to rise the demand of
immunoassay instruments
The key players operating the
immunoassay market are Siemens, Roche Diagnostics, Abbott Laboratories, Danaher
Corporation, and BioMérieux SA. The innovative measures adopted by the leading
manufacturers to perform different assays in a short time with minimal operator
intervention leads to the rising demand by the manufacturers. For instance, the
launch of automated immunoassay instrument working on the principle of
chemiluminescence Architect i1000SR by Abbott offers high precision, good
performance, and low detection limits. Other key vendors operating the market
are Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd, Siemens Medical
Solutions Diagnostics, and Trinity Biotech.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/942
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment